Debiopharm
Pharmaceuticals - Lausanne, Vaud, Switzerland
Debiopharm Details
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe. Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. Debiopharm completed the development and licensed out 2 compounds:- Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl®-Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®If you have interesting molecules and seek a competent and committed partner to develop them, please contact us.
Debiopharm Technologies
Email Providers
Outlook
Marketing Automation
Pardot
Load Balancers
Apache
CMS
WordPress.org
Email Delivery
MailJet
Recruitment
Workable